Your browser doesn't support javascript.
loading
Uncommon Presentation of Atypical Hemolytic Uremic Syndrome: A Case Report.
Martin, Sandra M; Balestracci, Alejandro; Puyol, Iris; Toledo, Ismael; Cao, Gabriel; Arizeta, Gema.
Afiliação
  • Martin SM; Nephrology Unit, Hospital General de Niños Pedro de Elizalde, Montes de Oca 40, Ciudad Autónoma de Buenos Aires, Barcelona, España, Argentina.
  • Balestracci A; Nephrology Unit, Hospital General de Niños Pedro de Elizalde, Montes de Oca 40, Ciudad Autónoma de Buenos Aires, Barcelona, España, Argentina.
  • Puyol I; Nephrology Unit, Hospital General de Niños Pedro de Elizalde, Montes de Oca 40, Ciudad Autónoma de Buenos Aires, Barcelona, España, Argentina.
  • Toledo I; Nephrology Unit, Hospital General de Niños Pedro de Elizalde, Montes de Oca 40, Ciudad Autónoma de Buenos Aires, Barcelona, España, Argentina.
  • Cao G; Division of Pathology, Hospital General de Niños Pedro de Elizalde, Montes de Oca 40, Ciudad Autónoma de Buenos Aires, Argentina.
  • Arizeta G; Department of Pediatric Nephrology, Hospital Vall d'Hebron, Universidad Autónoma de Barcelona, Passeig de la Vall d'Hebron 119, Barcelona, España, Argentina.
Indian J Nephrol ; 31(5): 478-481, 2021.
Article em En | MEDLINE | ID: mdl-34880559
ABSTRACT
Atypical hemolytic uremic syndrome (aHUS) is an ultra-rare disease characterized by microangiopathic hemolytic anemia, thrombocytopenia and renal damage. Its presentation as nephrotic syndrome (NS) during first year of life is uncommon; we describe a child with clinical and laboratory findings of NS whose renal biopsy revealed thrombotic microangiopathy (TMA). A previously healthy 4-month-old male was admitted with severe dehydration, diarrhea and anuria. Laboratory results showed electrolyte disturbances, increased serum creatinine, anemia without schistocytes, thrombocytosis, normal lactic dehydrogenase (LDH) levels, hypoalbuminemia hypercholesterolemia and decreased C3 levels. After rehydration hematuria and massive proteinuria were also documented and an initial diagnosis of NS of the first year was established. Studies seeking for infectious agents were negative. During hospitalization he continued to be oligo-anuric needing dialysis and a renal biopsy was performed, which showed TMA findings. We here considered the diagnosis of aHUS and started plasma infusions as a bridge until starting eculizumab. After two infusions urine output improved leading to discontinuation dialysis. The diagnoses of STEC infection and thrombocytopenic thrombotic purpura were ruled out. Factor B, H, I and properdin levels were normal. Antibodies against CFH negative were negative. Screening for genes causative of aHUS detected a heterozygous variant in CFHR3 of uncertain significance. On day 20, treatment was switched to eculizumab, which induced a progressive remission of the NS. This case outlines the need for a heightened diagnosis suspicion of this already rare disease since early initiation of eculizumab therapy improves its prognosis.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Indian J Nephrol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Argentina

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Indian J Nephrol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Argentina